Shaygannejad Vahid, Janghorbani Mohsen, Ashtari Fereshteh, Zakeri Hasanali
Department of Neurology, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Neurol Res. 2012 Nov;34(9):854-8. doi: 10.1179/1743132812Y.0000000081. Epub 2012 Sep 12.
The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS).
A 10-week, randomized double-blind crossover clinical trial conducted from October 2009 to September 2010. Fifty-two patients with MS presenting fatigue at 21 to 53 years of age were randomly allocated to the two treatment groups. The first group received amantadine (100 mg twice daily) for a total of 4 weeks. The second group received ASA (500 mg once daily) for four weeks. After a 2-week washout period, they crossed over to the alternative treatment for 4 weeks. Patients were rated at baseline and the end of each phase with the Fatigue Severity Scale (FSS).
ASA appeared to be equivalent in efficacy and safety to amantadine. A significant decrease in FSS occurred in both groups. Of the 26 patients treated with amantadine, the mean (SD) of FSS decreased from 4·8 (1·4) to 4·0 (1·4) (P<0·001). In the 26 patients treated with ASA, the mean (SD) of FSS decreased from 4·6 (1·4) to 3·5 (1·5) (P<0·001).
This study demonstrates that both ASA and amantadine significantly reduce MS-related fatigue. Both ASA and amantadine have previously been shown to reduce fatigue, and we postulate that treatment with ASA and amantadine may have similar benefits.
本研究旨在比较乙酰水杨酸（ASA）和金刚烷胺治疗多发性硬化症（MS）疲劳的相对疗效。
2009年10月至2010年9月进行了一项为期10周的随机双盲交叉临床试验。52例年龄在21至53岁之间出现疲劳症状的MS患者被随机分配到两个治疗组。第一组接受金刚烷胺（每日两次，每次100毫克），共4周。第二组接受ASA（每日一次，每次500毫克），共4周。经过2周的洗脱期后，他们交叉接受替代治疗4周。在基线和每个阶段结束时，使用疲劳严重程度量表（FSS）对患者进行评分。
ASA在疗效和安全性方面似乎与金刚烷胺相当。两组的FSS均显著降低。在接受金刚烷胺治疗的26例患者中，FSS的均值（标准差）从4.8（1.4）降至4.0（1.4）（P<0.001）。在接受ASA治疗的26例患者中，FSS的均值（标准差）从4.6（1.4）降至3.5（1.5）（P<0.001）。
本研究表明，ASA和金刚烷胺均可显著减轻与MS相关的疲劳。此前已证明ASA和金刚烷胺均可减轻疲劳，我们推测ASA和金刚烷胺治疗可能具有相似的益处。
